Europe Schizophrenia Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Schizophrenia patients study in a new report ‘Europe Schizophrenia Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Schizophrenia epidemiology, Schizophrenia diagnosed patients, and Schizophrenia treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Schizophrenia derived from epidemiological analysis, percentage of patients diagnosed with Schizophrenia, and percentage of patients treated with a therapy.
The study helps executives estimate Schizophrenia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Schizophrenia prevalence, Schizophrenia diagnosis rate, and Schizophrenia treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.